GTC Biotherapeutics (fka GTCB)

[DewDiligence]

I’m not clear on what you’re disagreeing with.

GTC needs milestone revenue coming in from Merrimack-like deals during the next 2-3 years. Without such revenue, GTC would be relying almost completely on the U.S. Atryn program to remain financially strong because the payoffs from the DIC/sepsis program and anything having to do with LFB will come later.

Although I think ATryn has an excellent chance to be approved by the FDA and to become a decent-selling drug in the U.S., I don’t want GTC’s medium-term fortunes to depend entirely on any one program.

The way I see it, more Merrimack-like deals are not just desirable—they are essential.